PhytoCandd_GI2-CESPU-2023 - Preventive and therapeutic potential of novel plants extracts in oral candidiasis
admin-cespu
Principal Investigator:
Célia Fortuna
Leader Institution:
1H-TOXRUN - CESPU
Research Team:
José Carlos Andrade; Paulo Alexandre Martins de Abreu Rompante; Marie Odile Madeleine Maziere; Lilian Barros; Nuno Filipe Azevedo; Andreia Azevedo
Funding entity:
CESPU
Budget:
3.500€
Period covered:
22.04.2024 - 21.04.2025
Abstract:
Both the WHO and UN stress that oral diseases are among the most common non-communicable diseases, affecting ~3.5 billion people worldwide, with billions of $ spent yearly.In oral biofilms, microorganisms form a highly complex community, increasing up to 1000 times the tolerance to drugs.This impacts the patients’ oral and systemic health, leading to the global rise in infections and antimicrobial resistance(AMR). C. albicans and non-C. albicans Candida spp. are amid the most common microorganisms involved in infections of the oral cavity, mostly in immunosuppressed patients.The rise of AMR has driven the researchers to focus on natural compounds, with bioactivity and new mechanisms of action.This proposal plans to select and test novel plant extracts(PE)- never tested in Candida sp. biofilms -to treat oral candidiasis(OC).The planktonic/biofilm PE susceptibility will be evaluated(MIC/MFC/MBEC), biofilm matrix changes will be measured (eg CLSM/SEM),and potential synergies among the best PEs will be assessed. Natural therapeutic lines may improve the prevention/treatment of OC, reducing the risk for AMR and socioeconomic costs, improving the quality of life and survival of patients.
Both the WHO and UN stress that oral diseases are among the most common non-communicable diseases, affecting ~3.5 billion people worldwide, with billions of $ spent yearly.In oral biofilms, microorganisms form a highly complex community, increasing up to 1000 times the tolerance to drugs.This impacts the patients’ oral and systemic health, leading to the global rise in infections and antimicrobial resistance(AMR). C. albicans and non-C. albicans Candida spp. are amid the most common microorganisms involved in infections of the oral cavity, mostly in immunosuppressed patients.The rise of AMR has driven the researchers to focus on natural compounds, with bioactivity and new mechanisms of action.This proposal plans to select and test novel plant extracts(PE)- never tested in Candida sp. biofilms -to treat oral candidiasis(OC).The planktonic/biofilm PE susceptibility will be evaluated(MIC/MFC/MBEC), biofilm matrix changes will be measured (eg CLSM/SEM),and potential synergies among the best PEs will be assessed. Natural therapeutic lines may improve the prevention/treatment of OC, reducing the risk for AMR and socioeconomic costs, improving the quality of life and survival of patients.